Education
About Us
Working with TipRanks
Follow Us
Xeris Pharmaceuticals (XERS)
NASDAQ:XERS
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 203.07M | $ 163.91M | $ 110.25M | $ 110.25M | $ 49.59M |
| Gross Profit | $ 166.24M | $ 135.27M | $ 87.61M | $ 87.61M | $ 36.27M |
| Operating Income | $ -33.65M | $ -44.01M | $ -81.94M | $ -81.94M | $ -115.16M |
| EBITDA | $ -13.99M | $ -23.73M | $ -69.31M | $ -113.67M | $ -80.08M |
| Net Income | $ -54.84M | $ -62.26M | $ -94.66M | $ -94.66M | $ -122.72M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 71.62M | $ 72.45M | $ 121.97M | $ 121.97M | $ 102.43M |
| Total Assets | $ 323.06M | $ 322.60M | $ 344.52M | $ 344.52M | $ 304.36M |
| Total Debt | $ 271.45M | $ 229.19M | $ 198.06M | $ 198.06M | $ 88.07M |
| Net Debt | $ 199.83M | $ 161.74M | $ 76.09M | $ 76.09M | $ 20.80M |
| Total Liabilities | $ 352.68M | $ 329.38M | $ 299.33M | $ 299.33M | $ 209.13M |
| Stockholders' Equity | $ -29.61M | $ -6.78M | $ 45.19M | $ 45.19M | $ 95.23M |
| Cash Flow | |||||
| Free Cash Flow | $ -37.85M | $ -49.29M | $ -103.42M | $ -103.42M | $ -96.62M |
| Operating Cash Flow | $ -36.98M | $ -47.02M | $ -102.89M | $ -102.89M | $ -95.53M |
| Investing Cash Flow | $ 4.88M | $ -6.00M | $ 34.46M | $ 34.46M | $ 97.96M |
| Financing Cash Flow | $ 36.17M | $ -1.61M | $ 127.47M | $ 127.47M | $ 27.25M |